DEFRA Delayed-release Capsule
Dimethyl fumarate
120 mg
Macleods Pharmaceuticals Ltd.
| Pack size | 14's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 28.89 AED |
Available as:
Indications
DEFRA Delayed-release Capsule is used for:
Used in multiple sclerosis patients with relapsing forms.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Dimethyl fumarate :
Mechanism of Action
The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF). MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. As well MMF is an agonist at the nicotinic acid receptor, but the relevance of this is not known.
Note
DEFRA 120 mg Delayed-release Capsule manufactured by Macleods Pharmaceuticals Ltd.. Its generic name is Dimethyl fumarate. DEFRA is availble in Saudi Arabia.
Farmaco SA drug index information on DEFRA Delayed-release Capsule is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.